File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: HMGCo-A Reductase Inhibitors increase Bone Formation

TitleHMGCo-A Reductase Inhibitors increase Bone Formation
Authors
Issue Date2006
PublisherOxford University Press
Citation
The 82nd Congress of the European Orthodontic Society, Vienna, Austria, 4 – 8 July 2006. In The European Journal of Orthodontics, 2006, v. 28 n. 6, p. e276 Abstract no.337 How to Cite?
AbstractAIM: A well-rounded alveolar ridge is required for orthodontic tooth movement. Statin, a HMG-CoA reductase inhibitor, has been shown to turn on the gene for bone formation by blocking the mevalonate pathway in cholesterol production. Naringin is a fl avonoid commonly available in citrus fruits, which is also a HMG-CoA reductase inhibitor. The aim of this study was to compare the amount of new bone produced by HMG-CoA reductase inhibitors, statin and naringin, in collagen matrix carrier with that of collagen matrix carrier alone. MATERIALS AND METHOD: Twenty bone defects were created in the parietal bone of 12 New Zealand white rabbits. In the experimental groups, fi ve defects were grafted with statin solution mixed with collagen matrix carrier and fi ve with naringin solution mixed with collagen matrix carrier. In the control groups, fi ve defects were grafted with collagen matrix carrier alone (positive control) and fi ve were left empty (negative control). The animals were killed on day 14 and the defects were dissected and prepared for histological assessment. Serial sections were cut across each defect. Quantitative analysis of new bone formation was made on 150 sections (50 sections for each group) using image analysis. RESULTS: A total of 308 and 490 per cent more new bone was present in the defects grafted with statin in collagen matrix carrier and naringin in collagen matrix carrier, respectively, than those grafted with collagen matrix carrier. No bone was formed in the passive control group. CONCLUSIONS: HMGCo-A reductase inhibitors, such as statin and naringin in collagen matrix carriers, have the effect of increasing new bone formation locally and can be used as bone graft materials. This has potential, as statin is a commonly prescribed cholesterol-lowering drug, whereas naringin is commonly available in edible fruits.
Persistent Identifierhttp://hdl.handle.net/10722/94132
ISSN
2015 Impact Factor: 1.44
2015 SCImago Journal Rankings: 1.090

 

DC FieldValueLanguage
dc.contributor.authorWong, RWKen_HK
dc.contributor.authorRabie, ABMen_HK
dc.date.accessioned2010-09-25T15:22:20Z-
dc.date.available2010-09-25T15:22:20Z-
dc.date.issued2006en_HK
dc.identifier.citationThe 82nd Congress of the European Orthodontic Society, Vienna, Austria, 4 – 8 July 2006. In The European Journal of Orthodontics, 2006, v. 28 n. 6, p. e276 Abstract no.337-
dc.identifier.issn0141-5387-
dc.identifier.urihttp://hdl.handle.net/10722/94132-
dc.description.abstractAIM: A well-rounded alveolar ridge is required for orthodontic tooth movement. Statin, a HMG-CoA reductase inhibitor, has been shown to turn on the gene for bone formation by blocking the mevalonate pathway in cholesterol production. Naringin is a fl avonoid commonly available in citrus fruits, which is also a HMG-CoA reductase inhibitor. The aim of this study was to compare the amount of new bone produced by HMG-CoA reductase inhibitors, statin and naringin, in collagen matrix carrier with that of collagen matrix carrier alone. MATERIALS AND METHOD: Twenty bone defects were created in the parietal bone of 12 New Zealand white rabbits. In the experimental groups, fi ve defects were grafted with statin solution mixed with collagen matrix carrier and fi ve with naringin solution mixed with collagen matrix carrier. In the control groups, fi ve defects were grafted with collagen matrix carrier alone (positive control) and fi ve were left empty (negative control). The animals were killed on day 14 and the defects were dissected and prepared for histological assessment. Serial sections were cut across each defect. Quantitative analysis of new bone formation was made on 150 sections (50 sections for each group) using image analysis. RESULTS: A total of 308 and 490 per cent more new bone was present in the defects grafted with statin in collagen matrix carrier and naringin in collagen matrix carrier, respectively, than those grafted with collagen matrix carrier. No bone was formed in the passive control group. CONCLUSIONS: HMGCo-A reductase inhibitors, such as statin and naringin in collagen matrix carriers, have the effect of increasing new bone formation locally and can be used as bone graft materials. This has potential, as statin is a commonly prescribed cholesterol-lowering drug, whereas naringin is commonly available in edible fruits.-
dc.languageengen_HK
dc.publisherOxford University Press-
dc.relation.ispartofThe European Journal of Orthodonticsen_HK
dc.titleHMGCo-A Reductase Inhibitors increase Bone Formationen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailWong, RWK: fyoung@hkucc.hku.hken_HK
dc.identifier.emailRabie, ABM: rabie@hkusua.hku.hken_HK
dc.identifier.authorityWong, RWK=rp00038en_HK
dc.identifier.authorityRabie, ABM=rp00029en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/ejo/cjl095-
dc.identifier.hkuros117137en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats